1. Amgen buying drug discovery biotech Nuevolution for $167M — Novartis’ asthma drug beats GSK’s Advair in trial — Lilly’s mirikizumab succeeds in phase 2 Crohn’s trial -- See more on our front page news

    Got questions about whistleblowing?: Ask a Whistleblower Attorney
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

AbbVie stock down 1.8% in premarket trade after failure of glioblastoma drug trial

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 17, 2019 at 11:12 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Nov 21, 2001
    Likes Received:
    via Shares of AbbVie Inc. ABBV, +0.08% fell 1.8% in premarket trade after the company announced that interim data from a Phase 3 trial of glioblastoma drug Depatux-M did not show any survival benefit to patients.

    article source